Serum ferritin in patients with malignant neoplasms

Serum ferritin levels were studied in 264 patients who were consisted of 153 patients with various malignant neoplasms and 111 patients with various benign diseases. Positive rate of serum ferritin in all patients with malignant neoplasms was 35%. Hepatomas and pulmonary cancer showed relatively high positive rate, respectively 65% and 42%. In patients with benign diseases, hepatic diseases showed the high positive rate (52%) and the other benign diseases was low positive rate (11%). The relationship between serum ferritin and alpha-feto-protein in patients with hepatomas and other liver diseases was low. And the relationship between serum ferritin and CEA (carcinoembryonic antigen) in patients with malignant neoplasms of gastrointestinal tract was also low. It seemed that the measurement of serum ferritin levels will be of low value in the differentiation of the patients with malignant neoplasms.     

A fundamental and clinical study of ferritin 'Eiken' radioimmunoassay kit

We have measured serum ferritin level using double antibody radioimmunoassay kit (Eiken ICL) and evaluated the characteristics of the kit and clinical usefulness. Satisfactory results were observed in standard curve, reproducibility, dilution and recovery test. In clinical evaluation, we have measured in normal subjects and patients with various diseases. The range in normal males and females were 13.0-158.7 ng/ml and 7.3-73.0 ng/ml, respectively. Serum ferritin level was elevated in patients with hepatoma, biliary cancer, lung cancer and other malignant diseases. Measurement of serum ferritin value would be useful in the monitoring of cancer patients.     

Immunochemical measurement and immunohistochemical detection of membrane-associated placental tissue protein 1

Using the avidin-biotin binding system, an enzyme immunoassay procedure was developed to measure the membrane-associated placental tissue protein 1 (MP1) in serum. The standard curve covered the range from 10 to 1000 ng/ml of MP1. The intra- and inter-assay coefficient of variations (C.Vs) were less than 5 and 10%, respectively. Recoveries of MP1 added to serum ranged between about 96 and 101%. The MP1 serum level was over 10 and under 112 ng/ml in non-pathological men, and under 240 ng/ml in non-pathological women. The MP1 level in the ovulatory phase was higher than in other phases of the menstrual cycle. In pregnancies during 6-39 weeks, the MP1 level ranged from 10 to 540 ng/ml, and it increased during the third trimester of gestational age. In benign gynecologic diseases, the MP1 concentration in serum ranged from 10 to 215 ng/ml. The MP1 levels in benign diseases were compared with those in ovarian malignancies, in endometrial carcinoma, and in uterine cervical cancer. The immunohistochemical location of MP1 was detected in the cell membrane of ovarian cystadenocarcinoma.     

Development of radioimmunoassay of intact laminin and its clinical evaluation as a tumor marker.

The concentration of laminin including laminin variants in serum samples was measured by a double-antibody radioimmunoassay using intact laminin. The mean level in 92 normal subjects (47 men and 45 women) was defined as 1 unit (U)/ml, and the cut-off value (2 S.D. above the mean) was 1.37 U/ml. Mean laminin level in 391 patients with various malignancies was 1.50 +/- 0.86 U/ml. Laminin levels were elevated in various cancer patients, and in 45.0% (176/391) the values exceeded the cut-off level; in patients with cancer of the stomach or pancreas, positivity rate exceeded 60%. Mean laminin concentration for 130 pregnant women (2.06 +/- 0.65 U/ml) was also significantly higher than that of normal controls, but concentrations for patients with various benign diseases were within a low range (0.55 +/- 0.29-1.10 +/- 0.29 U/ml). In the stomach or pancreas cancer patients, a positive correlation between laminin level and tumor progression or course of the disease was observed. These findings indicate that serum laminin level is potentially useful in the diagnosis and monitoring of certain cancers.     

Purification and determination of human prostate specific antigen in the serum

A human prostate specific antigen (PA) has been purified from an extract of prostatic tissue obtained during operation for benign prostatic hypertrophy (BPH). The antigen, which can be demonstrated a single component by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), has an apparent molecular weight of about 34,000 and has lower mobility for the positive pole than prostatic acid phosphatase (PAP). Double antibody radioimmunoassay (RIA) for PA in serum was developed with the antiserum raised in rabbit against partially purified PA. In normal serum of 30 controls the concentration were studied by the RIA. The normal upper limit of the serum PA levels in assay was set at 2.5 ng/ml. Elevated levels were observed in serum from 19 out of 21 untreated patients with prostatic carcinoma and 9 out of 23 patients with BPH, but latter less than 10 ng/ml. The results indicate that the PA is a potentially useful marker as well as PAP for prostatic cancer.     

Basic and clinical evaluation of a new assay procedure "SCC RIABEAD" for estimation of squamous cell carcinoma related antigen

We examined the efficacy of a new commercial assay procedure (SCC RIABEAD) for estimation of squamous cell carcinoma related antigen (SCC). Intraassay and interassay variance were 4.0-14.6% and 4.6-17.0% respectively. Recovery and dilution tests gave satisfactory results. The normal range was under the level of 1.63 ng/ml. The patients with uterine cervical cancer or squamous cell carcinoma of the lung showed high positive rates. The values of SCC measured by SCC RIABEAD were well-correlated to those by SCC RIAKIT. However, SCC RIABEAD showed lower values in low SCC level and higher values in high SCC level than SCC RIAKIT.     

A study on postsplenectomy changes of serum tuftsin level using a radioimmunoassay protocol

In this article, postsplenectomy changes of serum tuftsin level were studied on both human subjects and rabbits by using a self-established radioimmunoassay protocol. Antituftsin antibodies were raised in rabbits and roosters.¹²⁵I-tuftsin was prepared through an Iodogen method. The characteristics of the RIA were satisfactory with a detecting range of 0.5–100 ug/ml and the lowest detection limit of 400ng/ml. Serum tuftsin levels of splenectomized subjects were measured and compared with control groups. The serum tuftsin level from 30 postsplenectomy human beings was 406±179 ng/ml ( ± s) while that from a control group of 40 healthy blood donors was 557±256 ng/ml; the serum tuftsin level of 10 postsplenectomy rabbits was found to be 206±75 ng/ml while that of a control group of 10 normal rabbits was 318±96 ng/ml. The results showed that serum tuftsin level decreased markedly after splenectomy.     

双源CT双能量参数联合血清miR-126、miR-204检测对肺癌诊断价值及与临床病理特征关联性

回顾性选取肺癌患者86例为肺癌组,同期肺良性结节患者86例为对照组,患者均行双源CT双能量、血清miR-126、miR-204水平检测,发现静脉期标准化碘浓度(NIC)、动脉期NIC、miR-204、miR-126水平在肺癌组中呈异常表达,并与肺癌组病理类型、临床分期、淋巴结转移存在一定相关性,三者联合对肺癌具有一定诊...     

孤立性肺结节的CT形态学特征结合GSI模式的诊断学研究

本研究探讨CT联合能谱成像(GSI)模式诊断孤立性肺结节的临床价值。选取经肺穿刺活检或手术病理学证实的肺孤立性结节患者110例(110个肺结节),对患者的CT平扫、GSI平扫资料进行分析。根据病理学结果分为良性组(炎性结节、非典型腺瘤样增生)41例、恶性组(肺癌小结节)69例,对比两组患者的肺小结节形态学特征综合评分、动静脉期的能谱曲线斜率、40 keV CT值、标准化碘浓度(NIC)的差异。结果显示,恶性组患者的毛刺征和棘突征、分叶征、血管集束征、胸膜凹陷征、支气管征、病灶内钙化、病灶强化值及孤立性肺结节形态学特征总分均高于良性组(P<0.05);恶性组患者的动脉期、静脉期的能谱曲线斜率、40 keV CT值、NIC均低于良性组(P<0.05)。肺部孤立性恶性结节的形态学特征与肺部良性结节差异显著,恶性结节的能谱曲线斜率、40 keV CT值、NIC值与良性结节差异明显。因此,综合分析结节的形态学特征及GSI参数对其良恶性诊断具有重要意义。     

Fundamental studies on thyroid stimulating hormone immunoradiometric assay kit (TSH RIABEAD II)

We have reported fundamental studies on the TSH immunoradiometric assay, using TSH RIABEAD II kit (Dainabot). The sensitivity of the assay was 0.03 mu IU/ml and its C.V. was 27.2%. Intra- and inter-assay C.V. were less than 5%. Dilution test and recovery test were good. Serum TSH level was 0.3-4.0 mu IU/ml in normal subjects, less than 0.03 mu IU/ml in untreated Graves' disease and subacute thyroiditis. Therefore, it was found that the clear difference exist in serum TSH levels between normal subjects and patients with untreated Graves' disease. There was a well correlation on the serum TSH levels between this method and TSH radioimmunoassay kit (Amerlex TSH, r = 0.983). Especially, the measurement of serum TSH levels, using immunoradiometric assay kit, was useful for the diagnosis of patients with Graves' disease.     

Novel electrochemical sensor for the selective recognition of chlorogenic acid

In this article, we demonstrate the fabrication and simultaneous fluorescent detection of two biomarkers related to lung cancer. Polystyrene microspheres (PSM) were introduced as biomolecular immobilizing carriers and a 96-well filter plate was used as the separation platform. The whole experiment could be effectively carried out in a homogeneous system, as exemplified by the detection of carcinoembryonic antigen (CEA) and neuron specific enolase (NSE). First, two capture antibodies for CEA and NSE were immobilized on the PSM surface. Next, they reacted successively with two antigens and two modified detection antibodies. Finally, these two biomarkers could be recognized by streptavidin-conjugated quantum dots (QD) and goat-anti-FITC conjugated QD with a detection limit of 0.625 ng mL(-1), which was lower than the clinical cut-off level. The protocol showed good precision within 6.36% and good recovery in the range of 90.86-105.02%. Compared with several other assay formats reported previously, our new technique is competitive or even better. Furthermore, the immunosensor was successfully illustrated in 20 serum samples. Overall, this new immunoassay offers a promising alternative for the detection of biomarkers related to cancer diseases, taking advantage of simplicity, specificity, sensitivity and cost-efficiency.     

Importance of Bile Composition for Diagnosis of Biliary Obstructions

Determination of the cause of a biliary obstruction is often inconclusive from serum analysis alone without further clinical tests. To this end, serum markers as well as the composition of bile of 74 patients with biliary obstructions were determined to improve the diagnoses. The samples were collected from the patients during an endoscopic retrograde cholangiopancreatography (ERCP). The concentration of eight bile salts, specifically sodium cholate, sodium glycocholate, sodium taurocholate, sodium glycodeoxycholate, sodium chenodeoxycholate, sodium glycochenodeoxycholate, sodium taurodeoxycholate, and sodium taurochenodeoxycholate as well as bile cholesterol were determined by HPLC-MS. Serum alanine aminotransferase (ALT), aspartate transaminase (AST), and bilirubin were measured before the ERCP. The aim was to determine a diagnostic factor and gain insights into the influence of serum bilirubin as well as bile salts on diseases. Ratios of conjugated/unconjugated, primary/secondary, and taurine/glycine conjugated bile salts were determined to facilitate the comparison to literature data. Receiver operating characteristic (ROC) curves were determined, and the cut-off values were calculated by determining the point closest to (0,1). It was found that serum bilirubin was a good indicator of the type of biliary obstruction; it was able to differentiate between benign obstructions such as choledocholithiasis (at the concentration of >11 µmol/L) and malignant changes such as pancreatic neoplasms or cholangiocarcinoma (at the concentration of >59 µmol/L). In addition, it was shown that conjugated/unconjugated bile salts confirm the presence of an obstruction. With lower levels of conjugated/unconjugated bile salts the possibility for inflammation and, thus, neoplasms increase.     

Specific and sensitive determination of medroxyprogesterone acetate in human serum by gas chromatography-mass spectrometry

The mass fragmentographic determination of medroxyprogesterone acetate (MPA) in serum, using as internal standard medroxyprogesterone propionate (MPP) synthesized from MPA, is described. After addition of MPP, the sera are extracted on Sep-Pak C18 cartridges and MPA and MPP are detected as their respective 3-enol trifluoroacyl esters. Serum samples from 84 patients with breast cancer, daily receiving MPA orally, were determined showing a large variation in MPA concentrations (4-349 ng/ml). Our proposed gas chromatographic-mass spectrometric (GC-MS) method, which can be considered as a reference, was compared with a radioimmunoassay (RIA) method showing a correlation coefficient of 0.73 (n = 69; p much less than 0.001). The assay was also used to determine sequential serum levels of patients receiving a single oral dose of MPA. With only minor adjustments, the GC-MS method allows the determination of serum concentrations of related steroids such as megestrol acetate and cyproterone acetate.     

Myocardial injury occurs earlier than myocardial inflammation in acute experimental viral myocarditis

Endomyocardial biopsy often fails to show myocardial inflammation for patients with clinically suspected myocarditis. The serum isoforms of troponin T (cTnT) level is a very sensitive marker of myocardial injury and it is elevated even in the absence of myocardial inflammation. We investigated the correlations for myocardial injury, virus titers and inflammation in acute viral infection. Using the murine coxsackievirus group B3 (CVB3) myocarditis model, the histopathologic findings and virus titers in mouse hearts were compared with the serum cTnT levels measured by ELISA at various time points. Viable virus titers in the hearts peaked at 3 days after infection (8.22 +/- 0.13 log10 PFU/100 mg of heart); they decreased at day 7 and no viable virus was detected from day 14. Myocardial inflammation was minimal at day 3, peaked at day 7 and markedly decreased at day 14. The individual serum TnT levels were significantly increased at day 3 (7.37 +/- 1.46 ng/ml), persisted to day 7 (0.73 +/- 0.08 ng/ml), and normalized at day 14. Serum cTnT levels were correlatable with virus titers in the heart (r = 0.744, P <0.01), but the serum cTnT levels were not correlated with the degrees of inflammation. Using the less myocarditic strain of CVB3, similar relationships were observed between the changes for the serum cTnT levels and the heart virus titers. During the course of viral infection, myocardial injury precedes the pathologic evidence of inflammation, and the elevated cTnT levels provide evidence of myocardial injury even in the absence of any histologic findings of myocarditis.     

Sensitive method for the determination of the antiarrhythmic drug detajmium in serum by solid-phase extraction and high-performance liquid chromatography with fluorimetric detection.

The objective of this study was to develop a very sensitive and selective method for the determination of detajmium (4-3-diethylamino-2-hydroxypropyl-ajmaline), a sodium-channel-blocking drug with antiarrhythmic properties, in serum. A high-performance liquid chromatography (HPLC) method with solid-phase extraction and fluorimetric detection has been applied. Serum samples were diluted with phosphate buffer (pH 3.5) and the extraction of detajmium and ajmaline, which was used as an internal standard, was carried out with Oasis cartridges (Waters). The chromatographic separation was performed on a RP18 column. The limit of quantification for serum samples of detajmium was 1 ng/ml with good reproducibility (R.S.D. < 15%) and a linear response from 1 to 200 ng/ml. The described method is highly sensitive and specific for the determination of detajmium in serum of patients and volunteers.     

The Signal‐Enhanced Label‐Free Immunosensor Based on Assembly of Prussian Blue‐SiO2 Nanocomposite for Amperometric Measurement of Neuron‐Specific Enolase

A signal‐enhanced label‐free electrochemical immunosensor was constructed by the employment of Prussian blue doped silica dioxide (PB‐SiO₂) nanocomposite. At first, PB‐SiO₂ nanocomposite which was produced by using a microemulsion method was used to obtain a nanostructural monolayer on a glassy carbon electrode (GCE) surface. Next amino‐functionalized interface were prepared by self‐assembling 3‐aminopropyltriethoxy silane (APTES) on the PB‐SiO₂ nanoparticle surface. Then chitosan stabled gold nanoparticle (CS‐nanoAu) was subsequently attached, while the entire surface was finally loaded with neuron‐specific enolase antibody (anti‐NSE) via the adsorption of gold nanoparticle. The sensitivity of the proposed immunosensor has greatly improved as the PB‐SiO₂ nanostructural sensing film provides plenty of active sites which might catalyze the reduction of H₂O₂. The immunosensor exhibited good linear behavior in the concentration range from 0.25–5.0 and 5.0–75 ng/mL for the quantitative analysis of neuron‐specific enolase (NSE), a putative serum marker of small‐cell lung carcinoma (SCLC), with a limit of detection of 0.08 ng/mL. The resulting NSE immunosensor showed high sensitivity and long‐term lifetime which can be attributed to the extremely high catalytic activity and biocompatibility of CS‐nanoAu/APTES/PB‐SiO₂ nanostructural multilayers.     

超声弹性成像联合BI-RADS对微小(≤2cm)乳腺良恶性病变的鉴别价值

本文对超声弹性成像（UE）联合乳腺影像报告和数据系统（BI-RADS）对微小（≤2 cm）乳腺良恶性病变的鉴别价值进行了分析。研究对象选取2018年3月~2019年3月期间本院80例乳腺病变患者共112个病灶,所有患者均给予UE和BI-RADS检查,以病理检查为参照,分析UE、BI-RADS及二者联合对微小（≤2 cm）乳腺良恶性病变的鉴别价值。病理检查结果显示,112个病灶中,良性60个（53.57%）、恶性52个（46.43%）;恶性乳腺病变患者UE和BI-RADS评分明显高于良性患者,差异有统计学意义（P<0.05）。UE鉴别微小乳腺良恶性病变（≤2 cm）的敏感度为76.92%、特异度为76.67%、准确度为76.79%,BI-RADS的敏感度为80.77%、特异度为80.00%、准确度为80.36%,UE联合BI-RADS的敏感度、特异度、准确度分别为96.15%、95.00%、95.54%,可见UE联合BI-RADS的鉴别效果明显优异,差异有统计学意义（P<0.05）。本文证实了UE、BI-RADS对微小（≤2 cm）乳腺良恶性病变具有良好的鉴别价值,且二者联合的鉴别价值更高。     

Clinical usefulness of a trypsin radioimmunoassay kit

From the clinical use of RIA-gnost trypsin kit, the following results were obtained. 1. Standard curve showed a steep and good curve was shown. 2. Incubation: The condition for the first incubation was set at the room temperature for 10-24 hours and that for the second incubation at the room temperature for 3-5 hours. With these settings, satisfactory results were obtained. 3. Reproducibility and recovery: The C.V. of the reproducibility and the recovery were considered superior, and the values were below 10% and +/- 3%, respectively. 4. Correlation between trypsin and serum elestase-1: An excellent positive correlation (coefficient of correlation r = 0.889) was shown. 5. Serum trypsin concentration of normal and pancreatic diseases: The normal range was from 100 to 500 ng/ml. Acute pancreatitis rose obviously. Diabetes mellitus and chronic pancreatitis was below 500 ng/ml and the pancreatic cancer showed a tendency to scatter in the range of 50-1,250 ng/ml. The above results indicated that serum trypsin can be easily measured with high precision by using this method. Thus the method is considered useful for the diagnosis of pancreatic diseases.     

Simultaneous determination of gemcitabine and its main metabolite, dFdU, in plasma of patients with advanced non-small-cell lung cancer by high-performance liquid chromatography-tandem mass spectrometry

Gemcitabine, 2',2'-difluoro-2'-deoxycytidine (dFdC) is a pyrimidine antimetabolite employed against several human malignancies. It undergoes intracellular activation to the pharmacologically active triphosphate form (dFdCTP) and metabolic inactivation to the metabolite 2',2'-difluorodeoxyuridine (dFdU). In order to investigate the human plasma pharmacokinetics of dFdC and dFdU, we developed and validated an HPLC-MS/MS method, adding 2'-deoxycytidine as internal standard and simply precipitating the protein with acetonitrile. The method requires a small sample (125 microl), and it is rapid and selective, allowing good resolution of peaks from the plasma matrix in only 7 min. It is sensitive, precise and accurate, with overall precision, expressed as CV%, always less than 10.0% for both analytes and high recovery: > or = 80%. The limits of detection for dFdC and dFdU were 0.1 and 1.1 ng/ml, but considering the high concentrations in the plasma of patients investigated, we set the limit of quantitation at 20 ng/ml (0.08 microM) for dFdC and 250 ng/ml for dFdU, and validated the assay up to the dFdC concentration of 6.0 microg/ml (22.8 microM). The method was successfully used to study the drug pharmacokinetics in patients with advanced non-small-cell lung cancer in a phase II trial with gemcitabine administered as a fixed dose-rate infusion.     

Determining ProGRP and isoforms in lung and thyroid cancer patient samples: comparing an MS method with a routine clinical immunoassay

This paper compares two methods to determine the tumor marker progastrin-releasing peptide (ProGRP): as routine assay, the automated time-resolved immunofluorometric assay (TR-IFMA), which allows total ProGRP determination; and the immunocapture liquid chromatography selected reaction monitoring mass spectrometry (LC–SRM-MS) method, which additionally allows isoform differentiation. The investigation included 60 serum samples from patients suffering from various cancer diseases which may cause elevated ProGRP levels (small cell lung carcinoma; SCLC, non-small cell lung carcinoma; NCLC; and medullary thyroid cancer; MTC, as well as some with unspecific diagnosis). The two methods showed good correlation (R ²?=?0.887). However, the MS method determines the total ProGRP concentration systematically approximately 30 % lower than the TR-IFMA, implying that the absolute values generated by the methods are not interchangeable. The MS method gives additional information about isoform levels in the samples, providing novel insight into isoform expression on the protein level.